More positive data for novel VEGF blocker fruquintinib

14 November 2022

Positive results have been reported from the Phase III FRUTIGA trial of fruquintinib, a candidate under development by Sino-American cancer specialist Hutchmed (HKEX: 13), in partnership with Eli Lilly (NYSE: LLY).

The novel oral therapy is a VEGFR inhibitor that works by blocking new blood vessel growth in tumors. Hutchmed is testing the candidate in people with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The latest results show that the trial met one of the primary endpoints, with a statistically-significant improvement in progression-free survival (PFS), which is clinically meaningful.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK